What should I know first?

Risperidone is an antipsychotic medicine with actions at several receptors. This lesson focuses on dopamine D2 and serotonin type2 receptors, using the current U.S. Risperdal oral-product labeling.

Risperdal has specified uses including schizophrenia. This is an explanation of selected pharmacology, not a complete guide to its indications or serious safety warnings.

This is a mechanism lesson, not a complete medicine guide. A diagram cannot choose treatment, predict your response, or tell you how to change a prescription.

How Brain Cells Communicate

Dopamine and serotonin carry messages between cells. Each has several receptor types. A receptor is a protein that responds to a messenger; the response depends on the receptor and the cell around it.

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Receptor icons are teaching symbols, not protein structures. No individual response or whole-brain blockade is implied.
About this illustration

A messenger can activate its receptor and change signaling in the receiving cell. Different receptors produce different effects.

How the Medication Changes Signaling

An antagonist interferes with a messenger’s activation of a receptor. Risperidone acts as an antagonist at dopamine D2 and serotonin type2 receptors. Its active metabolite, 9-hydroxyrisperidone, also contributes to its clinical effects.

The two panels represent different receptor systems. They do not show that the medicine removes dopamine or serotonin, or blocks every signal everywhere.

Explore the mechanism

What does receptor antagonism mean?

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Static introduction. Receptor icons are teaching symbols, not protein structures. No individual response or whole-brain blockade is implied.
A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Before medicine: receptor responseA messenger can activate its receptor and change signaling in the receiving cell. Different receptors produce different effects.
A receptor with natural messenger and a separate terracotta medicine symbol above the membrane; intracellular proteins illustrate the downstream signaling context. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Risperidone: activation opposed: The crossbar marks opposition to receptor activation, not permanent closure.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Risperidone: activation opposed

    The crossbar marks opposition to receptor activation, not permanent closure.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Risperidone: dopamine D2Risperidone opposes activation at dopamine D2 receptors. The medicine marker sits beside the icon to avoid asserting a binding pose.
A receptor with natural messenger and a separate terracotta medicine symbol above the membrane; intracellular proteins illustrate the downstream signaling context. Serotonin: A messenger can change signaling through its receptor. 5-HT2 receptor: This receptor symbol identifies a function, not a molecular structure. Risperidone: activation opposed: The crossbar marks opposition to receptor activation, not permanent closure.
  1. Serotonin

    A messenger can change signaling through its receptor.

  2. 5-HT2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Risperidone: activation opposed

    The crossbar marks opposition to receptor activation, not permanent closure.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Risperidone: serotonin type2Risperidone also opposes activation at serotonin type2 receptors. This is a separate receptor system, drawn using the same visual convention.

What this model cannot tell us

Clinical mechanism uncertain

  • Clinical mechanism uncertain The clinical explanation remains uncertain.
  • Limits of inference An experimental result does not by itself predict one person’s treatment response.
Receptors are not the whole storyA receptor action alone does not explain the therapeutic response or predict side effects for an individual.

Static overview. Start the steps when you are ready.

Guide to the illustration: Outlines identify a cell membrane or target; arrows mark the direction explained in each caption. Medicine symbols are labels, not measured shapes or binding poses. No quantity, size or rate is to scale.

Read the complete sequence
  1. Before medicine: receptor response. A messenger can activate its receptor and change signaling in the receiving cell. Different receptors produce different effects.
  2. Risperidone: dopamine D2. Risperidone opposes activation at dopamine D2 receptors. The medicine marker sits beside the icon to avoid asserting a binding pose.
  3. Risperidone: serotonin type2. Risperidone also opposes activation at serotonin type2 receptors. This is a separate receptor system, drawn using the same visual convention.
  4. Receptors are not the whole story. A receptor action alone does not explain the therapeutic response or predict side effects for an individual.
Evidence and model limits

Current Risperdal oral-product SPL; receptor pharmacology is distinct from clinical trials and from an experimentally resolved structure.

Receptor icons are teaching symbols, not protein structures. No individual response or whole-brain blockade is implied.

A Closer Look at the Molecular Level

Known action: receptor antagonism is described in the product’s pharmacology. Other receptors are affected as well, so this is a selected view.

Clinical uncertainty: the label states that the mechanism in schizophrenia is unclear. Receptor binding is not a complete explanation of benefit, side effects or an individual’s experiences. No binding pose or affinity comparison is inferred.

Sources and References

The sources below support the specific medicine and experimental context described here. Drawings are original qualitative teaching models; positions, arrows and timing do not give atomic geometry, occupancy or rates.

  1. DailyMed: Risperdal oral products, updated May 2026

    Also cited as: DailyMed: Risperdal oral products, updated May2026.

  2. NIH: What Is a Neurotransmitter?

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top